<DOC>
	<DOCNO>NCT01210690</DOCNO>
	<brief_summary>The purpose observational study broaden knowledge know safety efficacy profile Keppra® ( Levetiracetam ) oral solution epileptic infant young 12 month treat accord routine clinical practice . Their data collect reach age 13 month .</brief_summary>
	<brief_title>Observational Study Infants Who Are Prescribed Treatment With Keppra® ( Levetiracetam ) Oral Solution</brief_title>
	<detailed_description>This non-interventional sentinel sit post-authorization safety study ( PASS ) aim collect additional data use Keppra® ( Levetiracetam ) oral solution clinical practice , efficacy safety Keppra® ( Levetiracetam ) infant young than12 month . Epileptic patient age 1 month 11 month inclusive invited participation non-interventional sentinel site PASS , physician decide initiate therapy Keppra® ( Levetiracetam ) oral solution ( 100 mg/ml bottle ) patient far treat Keppra® ( Levetiracetam ) longer 10 day . The patient follow data collect reach age 13 month .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>diagnosis epilepsy treat Keppra® Oral Solution age 1 month 11 month inclusive study baseline</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra® Oral Solution</keyword>
	<keyword>Keppra® Children</keyword>
</DOC>